David D. Gibbs

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Mark J. McKeage, Joachim von Pawel, Martin Reck et al. · British Journal of Cancer · 2008 · 125 citations · Full text

BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors

David D. Gibbs, Davinder S. Theti, Nadya Wood et al. · Cancer Research · 2005 · 101 citations · Full text

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

Mark J. McKeage, Martin Reck, Michael B. Jameson et al. · Lung Cancer · 2009 · 91 citations

Oncology, Medicine, Phase Ii Study +8

Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression

Brendon J. Coventry, PL Lee, David D. Gibbs et al. · British Journal of Cancer · 2002 · 74 citations · Full text

Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor.

Davinder S. Theti, Vassilios Bavetsias, Lorraine Skelton et al. · PubMed · 2003 · 54 citations

Folate Receptor, Chemoprevention Strategy, Oncogenic Agent +14